Last updated: August 6, 2026
Eltrombopag olamine is a mature, globally marketed oral thrombopoietin-receptor agonist sold primarily as Promacta in the United States and Revolade in international markets. Novartis has generated approximately $1 billion annually from the product in recent years, but sales are entering a structural decline as U.S. generic competition expands and European markets face price pressure. The product remains commercially relevant because it has multiple approved indications, established physician familiarity, and a differentiated oral formulation.
What is the current commercial status of eltrombopag olamine?
Eltrombopag olamine is the active pharmaceutical ingredient in Promacta and Revolade. It is an oral small-molecule thrombopoietin-receptor agonist that stimulates platelet production through the human c-Mpl receptor.
The principal approved uses include:
| Market |
Brand |
Major approved uses |
| United States |
Promacta |
Immune thrombocytopenia, hepatitis C-associated thrombocytopenia in selected treatment settings, acquired severe aplastic anemia, and first-line severe aplastic anemia with immunosuppressive therapy |
| European Union and other markets |
Revolade |
Immune thrombocytopenia, severe aplastic anemia, and thrombocytopenia associated with chronic hepatitis C in applicable jurisdictions |
The U.S. product is marketed under NDA 022291. FDA-approved dosage forms include oral tablets in 12.5 mg, 25 mg, 50 mg and 75 mg strengths, as well as an oral suspension formulation in certain markets and label versions. The product’s clinical value is strongest where sustained platelet production is required and where an oral alternative to injectable platelet-stimulating therapies has commercial or practical advantages. (U.S. Food and Drug Administration [FDA], 2024a)
How has Promacta and Revolade revenue changed over time?
Novartis product sales have remained near $1 billion annually, with the peak period occurring before broad generic erosion in the United States.
| Fiscal year |
Promacta/Revolade net sales, approximately |
Year-over-year direction |
| 2020 |
$1.0 billion |
Growth or stable |
| 2021 |
$1.1 billion |
Growth |
| 2022 |
$1.1 billion |
Stable to modest growth |
| 2023 |
$1.09 billion |
Slight decline |
| 2024 |
Approximately $1.0 billion |
Decline |
Figures are rounded from Novartis annual reporting and may differ slightly because of currency translation and reporting classifications. (Novartis, 2021, 2022, 2023, 2024)
The financial trajectory has four phases:
- Launch and indication expansion: Sales increased as Promacta moved beyond chronic immune thrombocytopenia into severe aplastic anemia and other hematology uses.
- Peak commercial maturity: Revenue stabilized around $1.1 billion as the product achieved broad international adoption.
- Pre-generic erosion: Sales growth slowed as treatment guidelines matured and competing thrombopoietin-receptor agonists gained share.
- Generic transition: U.S. generic entry and price competition began to reduce branded revenue, with further erosion expected as additional generic suppliers enter.
Promacta/Revolade represents roughly 2% of Novartis total annual sales based on recent company revenue of approximately $50 billion. The product is therefore financially material but not central to Novartis’ overall earnings profile. (Novartis, 2024)
What factors are driving the eltrombopag olamine market?
Expanding use in severe aplastic anemia
Severe aplastic anemia is the most important growth and defense market for eltrombopag outside chronic immune thrombocytopenia. The product can be used with immunosuppressive therapy in newly diagnosed patients and as a treatment option for patients who have failed immunosuppressive therapy.
The first-line setting is commercially valuable because treatment duration and patient volumes can be more predictable than in heavily pretreated immune thrombocytopenia. Clinical practice remains influenced by age, transplant eligibility, donor availability, disease severity and institutional protocols.
Oral administration
Eltrombopag is administered orally, while romiplostim is administered subcutaneously. Oral dosing can reduce injection burden and may support use in patients requiring long-term treatment. This advantage is balanced by administration restrictions related to polyvalent cations, food interactions and monitoring requirements.
Eltrombopag should be separated from products containing calcium, magnesium, aluminum, iron and other polyvalent cations because of chelation-related effects on absorption. This limits convenience for some patients and creates a practical disadvantage relative to drugs with fewer administration restrictions. (FDA, 2024a)
Multiple therapeutic alternatives
The competitive market includes:
| Product |
Active ingredient |
Company |
Key commercial distinction |
| Promacta/Revolade |
Eltrombopag olamine |
Novartis |
Oral, broad indication base |
| Nplate |
Romiplostim |
Amgen |
Injectable thrombopoietin-receptor agonist |
| Doptelet |
Avatrombopag |
Dova Pharmaceuticals/Sobi |
Oral agent with fewer food-related restrictions in some use cases |
| Tavalisse |
Fostamatinib |
Rigel Pharmaceuticals |
Oral therapy with a different mechanism |
| Mulpleta |
Lusutrombopag |
Shionogi |
Primarily used for thrombocytopenia before procedures in chronic liver disease |
| Immunosuppressive therapy |
Horse ATG plus cyclosporine |
Multiple suppliers |
Core comparator in severe aplastic anemia |
| Hematopoietic stem-cell transplant |
N/A |
Transplant centers |
Potentially curative option for selected aplastic anemia patients |
Avatrombopag is the most direct oral competitive threat. It can benefit from a simpler administration profile in some patients, while eltrombopag retains advantages from longer market experience, extensive clinical data and established guideline positioning.
When does eltrombopag olamine lose market exclusivity?
Eltrombopag has already moved beyond the period of primary branded exclusivity in the United States and Europe. The commercial issue is no longer whether generic competition will occur, but how quickly generic penetration will expand across dosage strengths, payers and channels.
The key exclusivity milestones were:
| Milestone |
Timing |
| U.S. approval of Promacta for immune thrombocytopenia |
2008 |
| U.S. approval for hepatitis C-associated thrombocytopenia |
2012 |
| U.S. approval for refractory severe aplastic anemia |
2014 |
| U.S. pediatric immune thrombocytopenia expansion |
2015 |
| U.S. first-line severe aplastic anemia approval |
2018 |
| Generic competition |
Emerging after the branded exclusivity and patent barriers weakened |
Orphan-drug exclusivity applied to certain indications, not indefinitely to the entire molecule. Each indication can have a separate exclusivity period, and pediatric exclusivity can add six months to applicable protection. Patent protection also depends on the specific formulation, strength, indication and jurisdiction. (FDA, 2024b)
What patents protect Promacta and Revolade?
The eltrombopag patent estate has included composition-of-matter, pharmaceutical composition, formulation and method-of-use claims. Protection has not been uniform across all markets or indications.
The principal commercially relevant patent categories are:
- Eltrombopag chemical structure and salts, including the olamine form.
- Pharmaceutical compositions containing eltrombopag olamine.
- Oral dosage forms and formulations.
- Methods for treating thrombocytopenia.
- Methods for treating severe aplastic anemia.
- Pediatric and disease-specific treatment methods.
The U.S. Orange Book is the controlling public source for patents listed against Promacta. It should be reviewed by dosage form and NDA because listed patents and expiration dates can differ across products and indications. FDA’s Orange Book does not establish that every listed patent is valid or infringed; it identifies patents submitted by the NDA holder under the Hatch-Waxman framework. (FDA, 2024c)
The strategic consequence is important: generic applicants can challenge some listed patents while designing around others. A generic product does not need to duplicate every branded method-of-use claim if it can rely on a narrower label or a section viii statement for a patented indication.
Which companies are challenging eltrombopag olamine?
The U.S. generic market has attracted ANDA applicants seeking approval for eltrombopag tablets. The competitive field is likely to include large generic manufacturers and specialty suppliers rather than a single first entrant.
The relevant challenge mechanisms are:
- Paragraph IV certification against listed patents.
- Section viii statements carving out patented indications.
- Paragraph III certifications for patents that remain in force.
- Abbreviated new drug applications for tablet strengths that match the reference product.
- Potential 180-day exclusivity for a qualifying first Paragraph IV filer.
A Paragraph IV filing can create patent litigation under Hatch-Waxman. The lawsuit may trigger a 30-month stay of FDA approval if filed within the statutory period, although the commercial effect depends on the patents asserted, claim scope and court outcome. (FDA, 2024d)
Publicly reported patent litigation and ANDA activity should be evaluated at the individual applicant level. The presence of a Paragraph IV filing does not establish an imminent launch because litigation, settlement terms, regulatory deficiencies and manufacturing readiness can delay entry.
What is the FDA regulatory status of eltrombopag?
Promacta has full FDA approval and is not dependent on accelerated approval for its principal U.S. indications. The product is supported by a mature safety and efficacy record and extensive post-market experience.
Key regulatory characteristics include:
- FDA approval under NDA 022291.
- Multiple tablet strengths.
- Pediatric use in specified immune thrombocytopenia populations.
- Severe aplastic anemia indications, including first-line use with immunosuppressive therapy.
- Label warnings concerning hepatotoxicity, thrombotic risk, cataracts, bone marrow reticulin and laboratory monitoring.
- No biosimilar pathway because eltrombopag is a chemically synthesized small molecule rather than a biologic.
Generic competitors will generally use the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. They do not need to repeat the full clinical development program required for the original NDA. (FDA, 2024a; FDA, 2024d)
How strong is the eltrombopag patent estate?
The patent estate is commercially weaker than it was during the product’s growth phase because the core molecule is mature and generic applicants can target individual strengths and indications. Its remaining defensive value comes from:
- Patent layering across dosage forms.
- Method-of-use claims in severe aplastic anemia.
- Regulatory exclusivity associated with specific pediatric or orphan indications.
- Manufacturing controls and supply-chain qualification.
- Physician and payer inertia favoring the established brand.
- Patient-management experience with dose adjustment and monitoring.
The estate is less defensible where generic products can launch with narrow labels, avoid later-issued indication claims or compete in unprotected tablet strengths. The principal risk is therefore staged erosion rather than a single binary loss of exclusivity.
What generic launch risks exist for Promacta?
Base case: rapid U.S. erosion
The most likely scenario is substantial U.S. branded erosion after generic approvals, particularly in pharmacy-benefit and Medicaid channels. Oral tablets are relatively easy to substitute once FDA-approved alternatives are available.
Downside case: multi-supplier price compression
If several generic suppliers launch within a short period, net prices can fall sharply. Specialty-distribution economics may slow substitution compared with mass-market primary-care drugs, but the effect remains negative for branded revenue.
Mitigating case: controlled specialty adoption
Novartis may preserve a portion of revenue through contracting, patient-support services, physician loyalty and continued use in complex aplastic anemia cases. These measures can slow unit conversion but generally do not prevent long-term price erosion.
How does eltrombopag compare with competing thrombopoietin-receptor agonists?
| Attribute |
Eltrombopag |
Romiplostim |
Avatrombopag |
| Route |
Oral |
Subcutaneous injection |
Oral |
| Core use |
Immune thrombocytopenia and aplastic anemia |
Immune thrombocytopenia |
Immune thrombocytopenia and selected thrombocytopenia settings |
| Market maturity |
High |
High |
Intermediate |
| Generic exposure |
Increasing |
Lower immediate small-molecule substitution risk |
Developing |
| Administration complexity |
Food and cation restrictions |
Clinic or home injection |
Generally simpler oral administration |
| Brand advantage |
Large evidence base and broad global footprint |
Injectable efficacy and established use |
Oral convenience and newer positioning |
Eltrombopag’s strongest commercial defense is its role in severe aplastic anemia, where treatment decisions are more specialized and less driven by automatic pharmacy substitution. Its most exposed market is chronic immune thrombocytopenia, where multiple alternatives and generic competition can increase payer leverage.
What licensing deals and ownership arrangements affect eltrombopag?
Eltrombopag originated from GlaxoSmithKline research and was commercialized by Novartis under arrangements between the companies. Novartis has retained responsibility for Promacta/Revolade commercialization and has reported the product within its Innovative Medicines portfolio. The historical licensing structure matters mainly for rights allocation and royalty economics; current market performance is driven by Novartis’ branded sales, generic entry and indication mix. (Novartis, 2005; Novartis, 2024)
What is the revenue outlook for eltrombopag olamine?
Promacta/Revolade revenue is likely to decline over the medium term, with the rate determined by U.S. generic penetration and international tender pricing.
| Driver |
Expected effect on revenue |
| U.S. generic approvals |
Strong negative |
| Continued severe aplastic anemia use |
Positive volume support |
| New oral competitors |
Negative share pressure |
| International tendering |
Negative price pressure |
| Brand clinical familiarity |
Moderately positive retention |
| Manufacturing complexity |
Potentially slows generic scale-up |
| New label expansion |
Limited upside because the product is mature |
The commercial trajectory is therefore a declining mature-brand profile rather than a growth pharmaceutical profile. The product can remain strategically important in hematology while contributing less to Novartis revenue and operating profit each year.
Key Takeaways
- Eltrombopag olamine is marketed as Promacta in the United States and Revolade internationally.
- Novartis revenue has remained near $1 billion annually but has begun to decline.
- Severe aplastic anemia is the product’s most important long-term branded defense.
- Chronic immune thrombocytopenia is more exposed to generic substitution and competition from romiplostim, avatrombopag and fostamatinib.
- Eltrombopag is a small molecule, so generic ANDA competition applies; biosimilar risk does not.
- The patent estate includes molecule, formulation and method-of-use protection, but the product is already in the generic transition phase.
- The most likely financial outcome is progressive U.S. price and volume erosion, partially offset by specialty hematology use and international demand.
- Promacta/Revolade is material to Novartis but represents only about 2% of group sales.
FAQs
Is eltrombopag olamine the same as Promacta?
Yes. Eltrombopag olamine is the active ingredient in Promacta and Revolade, subject to market-specific branding and labeling.
Can eltrombopag olamine be substituted with avatrombopag?
Clinical substitution requires a physician decision. The products have different labels, dosing requirements, safety considerations and evidence bases.
Does eltrombopag olamine have biosimilar competition?
No. Eltrombopag is a chemically synthesized small molecule. Competitive products are regulated as generics or new drugs, not biosimilars.
Why is severe aplastic anemia important to Promacta revenue?
The indication supports use in a specialized, high-severity disease where treatment decisions are less dependent on routine pharmacy substitution and where eltrombopag has an established role alongside immunosuppressive therapy.
Will generic eltrombopag eliminate Promacta sales?
No. Generic entry is expected to reduce branded volume and price, but some patients may remain on Promacta because of physician preference, specialty distribution, support programs, clinical history or payer-specific contracting.
References
Food and Drug Administration. (2024a). Promacta prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024b). Drugs@FDA: Promacta NDA 022291 regulatory history. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024d). Abbreviated new drug application approvals and Hatch-Waxman patent certifications. U.S. Department of Health and Human Services.
Novartis. (2005). Novartis and GlaxoSmithKline announce agreement concerning eltrombopag. Novartis AG.
Novartis. (2021). Annual report 2021. Novartis AG.
Novartis. (2022). Annual report 2022. Novartis AG.
Novartis. (2023). Annual report 2023. Novartis AG.
Novartis. (2024). Annual report 2024. Novartis AG.
